ROCHE HOLDING AG News

HHS Panel to Vote in Nov. on DMD Screening for Newborns

Seeking AlphaMay 10 06:44

Phanes Therapeutics, Inc. Announces Clinical Supply Agreement With Roche to Evaluate PT217 in Combination With an Anti-PD-L1 Therapy

PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ) is Roche's anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on evaluating

PR NewswireMay 9 05:30

Boy Given Pfizer Experimental Duchenne Muscular Dystrophy Therapy Dies

Seeking AlphaMay 8 04:16

UBS Sticks to Their Hold Rating for Roche Holding AG (RHHVF)

TipRanksMay 6 17:05

Regeneron Falls After Q1 Miss; Announces $3B Share Buybacks

Seeking AlphaMay 2 19:55

Express News | Roche ophthalmologic dual antibody farazimab approved in China

BreakingsApr 30 15:20

European Medicines Agency Committee Backs Roche's Subcutaneous Injection for Multiple Sclerosis

Roche (RO.SW, ROG.SW) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Ocrevus subcutaneous injection for multiple sclerosis

MT NewswiresApr 29 13:24

J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade

Seeking AlphaApr 29 01:00

Express News | According to the Ministry of Commerce's website, on April 26, Deputy Director Wang Yupeng met with Xu Jian, head of the China Corporate Affairs and Market Access Department of Roche Diagnostics. The two sides exchanged views on Roche's cooperation with Ch

BreakingsApr 26 17:13

Phase 3 clinical trial of Roche (RHHBY.US) major antibody therapy Ocrevus obtained positive data

Recently, Genentech (Genentech), a subsidiary of Roche (RHHBY.US), announced that its major antibody therapy Ocrevus obtained positive data in the phase 3 clinical study Ocarina II for the treatment of recurrent or primary progressive multiple sclerosis (RMS or PPMS). The results showed that the Ocrevus subcutaneous preparation, which only took two doses a year, almost completely suppressed clinical recurrence and brain lesions.

Zhitong FinanceApr 26 11:33

Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%

Chugai Pharmaceutical's (TYO:4519) parent company, Roche Holding, posted group sales of 14.4 billion Swiss francs for the first quarter, down 6% from 15.3 billion francs a year earlier, according to a

MT NewswiresApr 25 13:17

DZ BANK AG Sticks to Its Buy Rating for Roche Holding AG (RHHVF)

TipRanksApr 25 00:25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)

TipRanksApr 24 19:50

UBS Remains a Hold on Roche Holding AG (RHHVF)

TipRanksApr 24 19:05

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)

TipRanksApr 24 16:50

Roche Cuts Pipeline After Research Setbacks and Sales Drop

ROCHE Holding cut a fifth of its pipeline of experimental drugs in recent quarters as its new chief executive tries to revive growth after a series of research setbacks.

Business TimesApr 24 16:09

Roche Results, Outlook Don't Surprise -- Market Talk

0625 GMT - Roche's first-quarter sales were broadly in line with consensus with its eye drug Vabysmo as a growth driver, offset by a sales decline of its Covid-19 products, Jefferies analysts say in a

WSJApr 24 14:25

Correction to Roche Article

Sales at Roche's pharmaceutical and diagnostics divisions both fell 6%, to CHF10.92 billion and CHF3.48 billion, respectively. "Roche Sales Decline on Currency Hit," at 0534 GMT, misstated the figures

Dow JonesApr 24 13:58

Express News | Roche's CEO said Roche is open to mergers and acquisitions.

BreakingsApr 24 13:51

Roche Sales Decline on Currency Hit

By Helena Smolak Roche first-quarter sales declined amid weak demand for Covid-19 products and currency headwinds but slightly beat analysts expectations. The Swiss pharmaceutical giant said Wednesd

WSJApr 24 13:34